???global.info.a_carregar???
Fábio Fiúza Rosa, PhD, is Head of Research and co-founder of Asgard Therapeutics. With a double PhD in Experimental Biology and Biomedicine by the University of Coimbra (Portugal) and Lund University (Sweden), Fábio pioneered the use of cell reprogramming to induce dendritic cell fate in vivo. Fábio has filed 5 patents and won over 15 awards. He leads R&D activities focused on harnessing dendritic cell reprogramming technologies for cancer immunotherapy. Fabio’s ambition is to expand the reach of dendritic cell reprogramming to develop novel immunotherapies for the benefit of patients with solid tumors.
Ler resumo completo ↓
Identificação

Identificação pessoal

Nome completo
Fábio Alexandre Fiúza Rosa

Nomes de citação

  • Rosa, Fábio
  • Rosa F. F.

Identificadores de autor

Ciência ID
7015-18A9-714C
ORCID iD
0000-0002-7714-5852

Websites

Domínios de atuação

  • Ciências Médicas e da Saúde - Medicina Básica - Imunologia

Idiomas

Idioma Conversação Leitura Escrita Compreensão Peer-review
Inglês Utilizador independente (B1) Utilizador independente (B1) Utilizador independente (B1) Utilizador independente (B1)
Português Utilizador proficiente (C1) Utilizador proficiente (C1) Utilizador proficiente (C1) Utilizador proficiente (C1)
Formação
Grau Classificação
2018/01/01 - 2021
Concluído
 Doutoramento em Biologia Experimental e Biomedicina (Doutoramento)
Especialização em Immunology
Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
2016
Concluído
 Mestrado em Bioquímica (Mestrado)
Universidade de Coimbra Faculdade de Ciencias e Tecnologia, Portugal
"Direct Reprogramming of fibroblasts to Dendritic Cells for immunotherapy" (TESE/DISSERTAÇÃO)
 18
2014
Concluído
 Licenciatura em Biologia (Licenciatura)
Universidade de Coimbra Faculdade de Ciencias e Tecnologia, Portugal
"n/a" (TESE/DISSERTAÇÃO)
 14
Percurso profissional

Ciência

Categoria Profissional
Instituição de acolhimento 		Empregador
2021 - Atual Investigador principal (carreira) (Investigação) Asgard Therapeutics, Suécia
2018/01/01 - 2021 Investigador (Investigação) Universidade de Coimbra Instituto de Investigação Interdisciplinar, Portugal
Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal

Outros

Categoria Profissional
Instituição de acolhimento 		Empregador
2015/08/22 - 2016/09/19 Master's student (Biochemistry) under supervision of Dr. Carlos Filipe Pereira. Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
Projetos

Bolsa

Designação Financiadores
2025 - Atual REPRO-TILs: Breakthrough Neoantigen-specific Tumor-Infiltrating Lymphocyte Therapies Through Novel Dendritic Cell Reprogramming
101213733
Investigador responsável
European Innovation Council
Em curso
2024 - Atual RESYNC: Functional chemical reprogramming of cancer cells to induce antitumor immunity
101130218
Co-Investigador Responsável (Co-IR)
European Innovation Council
Em curso
2021 - Atual REPRogramming tumors INTo immune cells: a revolutionary gene therapy to treat cancer (REPRINT)
E!115376
Core Team Member
Horizon 2020
2021 - Atual Support Turning head and neck cancer into immune cells: preclinical validation and clinical plan of TrojanDC
1
Core team member
Vinnova
2021 - Atual Develop an intangible asset strategy for Smile Incubator companies
1
Core team member
Vinnova
2020 - Atual TrojanDC – Turning Tumors into Immune Cells: A Revolutionary Gene Therapy to Treat Cancer
1
Core team member
Lunds Universitet
2020 - Atual Developing a new cancer immunotherapy based on dendritic cell reprogramming
1
Outra
Novo Nordisk Denmark A/S
2019 - Atual Lund University Innovation VFT Funds
1
Core team member
2019 - Atual Horizon 2020 SME instrument Phase 1 Grant
TrojanDC
Core team member
2019 - Atual Novo Nordisk Exploratory Pre-Seed Grant
Novo Nordisk
Core team member
2020 - 2020 Vinnova Innovative Startups Step 2
1
Core team member
Vinnova
2019 - 2019 IPA4SME support for intellectual property (IP) valorisation and protection
COSME
Core team member
2019 - 2019 Sten K Johnson Stiftelse grant
Sten K Johnson Stiftelse
Core team member
2019 - 2019 Lund University Innovation IKS Accelerator grant 2019
Innovation IKS Accelerator
Core team member
2019 - 2019 Lund University Innovation VFT Funds
Innovation VFT
Core team member
2018 - 2018 Vinnova Innovative Startups to support Regulatory and IP strategy
Vinnova Innovative Startups
Outra
2018 - 2018 StemTherapy Lund Innovation award
StemTherapy Lund Innovation
Core team member
2017 - 2017 Centro2020 Project to protect intellectual property
WO-2018-185709-A1
Core team member
2017 - 2017 Entrepreneurship competition Montepio Acredita Portugal Health Prize
Montepio Acredita
Outra
2016 - 2016 Business Plan Competition Arrisca C
Arrisca C
Core team member
Produções

Publicações

Artigo em revista
  1. Ascic, Ervin; Åkerström, Fritiof; Sreekumar Nair, Malavika; Rosa, André; Kurochkin, Ilia; Zimmermannova, Olga; Catena, Xavier; et al. Autor correspondente: Rosa F. F.. "In vivo dendritic cell reprogramming for cancer immunotherapy". Science 386 6719 (2024): https://doi.org/10.1126/science.adn9083.
    10.1126/science.adn9083
  2. Zimmermannova, Olga; Ferreira, Alexandra G.; Ascic, Ervin; Velasco Santiago, Marta; Kurochkin, Ilia; Hansen, Morten; Met, Özcan; et al. "Restoring tumor immunogenicity with dendritic cell reprogramming". Science Immunology 8 85 (2023): https://doi.org/10.1126/sciimmunol.add4817.
    10.1126/sciimmunol.add4817
  3. Rosa F. F.; Pires, Cristiana F.; Kurochkin, Ilia; Halitzki, Evelyn; Zahan, Tasnim; Arh, Nejc; Zimmermannová, Olga; et al. "Single-cell transcriptional profiling informs efficient reprogramming of human somatic cells to cross-presenting dendritic cells". Science Immunology 7 69 (2022): https://doi.org/10.1126/sciimmunol.abg5539.
    10.1126/sciimmunol.abg5539
  4. Rosa F. F.; Pires, Cristiana; Zimmermannova, Olga; Pereira, Carlos-Filipe. Autor correspondente: Pereira, Carlos-Filipe. "Direct Reprogramming of Mouse Embryonic Fibroblasts to Conventional Type 1 Dendritic Cells by Enforced Expression of Transcription Factors". BIO-PROTOCOL 10 10 (2020): https://doi.org/10.21769/bioprotoc.3619.
    10.21769/bioprotoc.3619
  5. Pires, Cristiana F.; Rosa, Fábio F.; Kurochkin, Ilia; Pereira, Carlos-Filipe. "Understanding and Modulating Immunity With Cell Reprogramming". Frontiers in Immunology 10 (2019): http://dx.doi.org/10.3389/fimmu.2019.02809.
    10.3389/fimmu.2019.02809
  6. Pires, Cristiana F.; Rosa F. F.; Kurochkin, Ilia; Pereira, Carlos-Filipe. "Understanding and Modulating Immunity With Cell Reprogramming". Frontiers in Immunology 10 (2019): https://doi.org/10.3389/fimmu.2019.02809.
    10.3389/fimmu.2019.02809
  7. Rosa F. F.; Pires, Cristiana F.; Kurochkin, Ilia; Ferreira, Alexandra G.; Gomes, Andreia M.; Palma, Luís G.; Shaiv, Kritika; et al. "Direct reprogramming of fibroblasts into antigen-presenting dendritic cells". Science Immunology 3 30 (2018): https://doi.org/10.1126/sciimmunol.aau4292.
    10.1126/sciimmunol.aau4292
  8. Fábio F. Rosa; Cristiana F. Pires; Ilia Kurochkin; Alexandra G. Ferreira; Andreia M. Gomes; Luís G. Palma; Kritika Shaiv; et al. "Direct reprogramming of fibroblasts into antigen-presenting dendritic cells". Science Immunology 3 30 (2018): eaau4292-eaau4292. https://doi.org/10.1126/sciimmunol.aau4292.
    10.1126/sciimmunol.aau4292
Tese / Dissertação
  1. Rosa, Fábio Alexandre Fiúza. "Direct Reprogramming of Fibroblasts to Dendritic Cells for Immunotherapy". Mestrado, 2016. http://hdl.handle.net/10316/33773.

Propriedade Intelectual

Patente
  1. Nejc Arh, Beatriz Vaz, Fábio Rosa and Filipe Pereira. 2023. "RNA-based strategies for dendritic cell reprogramming and uses thereof".
    Pendente
  2. Fábio Rosa, Cristiana Pires and Filipe Pereira. 2023. "Constructs and vectors for reprogramming cells to cDC1 cells, compositions and methods thereof".
    Pendente
  3. Carlos-Filipe Pereira, Cristiana Pires, Fábio Rosa. 2021. "Compositions for reprogramming cells into plasmacytoid dendritic cells or interferon producing cells, methods and uses thereof".
  4. Carlos-Filipe Pereira, Cristiana Pires, Fábio Rosa, Luís Oliveira. 2021. "Compositions for reprogramming cells into dendritic cells type 2 competent for antigen presentation, methods and uses thereof.".
  5. Fábio Rosa, Olga Zimmermannova, Alexandra Ferreira, Ervin ASCIC, Cristiana Pires, Carlos-Filipe Pereira. 2021. "Reprogramming of cells to type 1 conventional dendritic cells or antigen presenting cells".
  6. Carlos-Filipe Pereira, Cristiana Pires, Fábio Rosa. 2017. "Compositions for reprogramming cells into dendritic cells or antigen presenting cells, methods and uses thereof".

Outros

Empresa spin-off
  1. 2018. Asgard Therapeutics. Immunotherapy, Cancer.
  2. 2017. BRT Blood Reprogramming Technologies.
Atividades

Participação em evento

Descrição da atividade
Tipo de evento 		Nome do evento
Instituição / Organização
2023 - 2023 What I wish I would have known: Advice from Alumni
Encontro
 PhD Day
Lunds Universitet, Suécia
2020 - 2020 Ideas Salon: Europe & Americas
Mesa-redonda
 World Congress of Science and Factual Producers
2020 - 2020 Entrepreneurship at the “What Else: A world of opportunities" What Else: A world of opportunities
2018 - 2018 Pharmaceuticals & Industry: From Research to development
Conferência
 IV Bioengineering Week
Distinções

Prémio

2024 Under 34 Changemaker Award – Innovation Path
2023 Rapidus & PwC 34 Under 34 Award 2020, 2021, 2022, 2023
2021 The Nova 111 List – Sweden – Healthcare & Life Sciences
2021 The Maja and Hjalmar Leander Foundation Award: Best PhD thesis
2020 Lund University and Sparbanken Skåne’s Honor Award 2020
Lunds Universitet, Suécia
2019 EMBO Travel Grant to attend the EMBO Workshop in Antigen Processing and Presentation
2019 EIT Health PhD Translational Fellowship
EIT Health, Alemanha
2019 Jury’s Best Pitch Award
EIT Health, Alemanha
2019 Best Pitch Award
NOME, Dinamarca
2018 Best poster presentation award
2017 Best oral presentation award
2017 PhD Scholarship (SFRH/BD/130845/2017)

Título

2020 Forbes 30 Under 30 Europe 2020: Science & Healthcare
Forbes, Portugal

Outra distinção

2017 1st BEB/Bluepharma Award
2016 Innocentive Challenge in immunology and development of novel immunotherapies (9933820), Second Place Award out of 195 international solvers.
2016 Bolsa de investigação (BIM: PTDC/BIMMED/0075/2014) no Laboratório de reprogramação celular e Hematopoiese, CNC/UC-Biotech, Universidade de Coimbra, Portugal.
Fundação para a Ciência e a Tecnologia, Portugal